Nuclear Mechanisms Involved in Endocrine Resistance

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Oct 4

PMID 34604071

Citations 9

Authors

Jurgen Dittmer

Affiliations

Soon will be listed here.

Abstract

Endocrine therapy is a standard treatment offered to patients with ERα (estrogen receptor α)-positive breast cancer. In endocrine therapy, ERα is either directly targeted by anti-estrogens or indirectly by aromatase inhibitors which cause estrogen deficiency. Resistance to these drugs (endocrine resistance) compromises the efficiency of this treatment and requires additional measures. Endocrine resistance is often caused by deregulation of the PI3K/AKT/mTOR pathway and/or cyclin-dependent kinase 4 and 6 activities allowing inhibitors of these factors to be used clinically to counteract endocrine resistance. The nuclear mechanisms involved in endocrine resistance are beginning to emerge. Exploring these mechanisms may reveal additional druggable targets, which could help to further improve patients' outcome in an endocrine resistance setting. This review intends to summarize our current knowledge on the nuclear mechanisms linked to endocrine resistance.

Citing Articles

Extracellular vesicles in the treatment and diagnosis of breast cancer: a status update.

Zhang X, Wang C, Yu J, Bu J, Ai F, Wang Y Front Endocrinol (Lausanne). 2023; 14:1202493.

PMID: 37534210 PMC: 10393036. DOI: 10.3389/fendo.2023.1202493.

SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition.

Zhou J, Zhu M, Wang Q, Deng Y, Liu N, Liu Y Commun Biol. 2023; 6(1):695.

PMID: 37414914 PMC: 10326080. DOI: 10.1038/s42003-023-05065-w.

Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones.

Liang D, Feng Y, Zandkarimi F, Wang H, Zhang Z, Kim J Cell. 2023; 186(13):2748-2764.e22.

PMID: 37267948 PMC: 10330611. DOI: 10.1016/j.cell.2023.05.003.

Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins.

Szabova L, Gordon M, Lu L, Pate N, Bassel L, Iacovelli A Breast Cancer Res. 2022; 24(1):75.

PMID: 36333737 PMC: 9636824. DOI: 10.1186/s13058-022-01566-4.

A CAF-Fueled TIMP-1/CD63/ITGB1/STAT3 Feedback Loop Promotes Migration and Growth of Breast Cancer Cells.

Dittmer A, Dittmer J Cancers (Basel). 2022; 14(20).

PMID: 36291767 PMC: 9599197. DOI: 10.3390/cancers14204983.

References

Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar V, Perna F . Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat Commun. 2016; 7:10442. PMC: 4748123. DOI: 10.1038/ncomms10442. View

Semenza G . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33(4):207-14. PMC: 3437546. DOI: 10.1016/j.tips.2012.01.005. View

Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B . Targeting Notch to target cancer stem cells. Clin Cancer Res. 2010; 16(12):3141-52. PMC: 3008160. DOI: 10.1158/1078-0432.CCR-09-2823. View

Risson E, Nobre A, Maguer-Satta V, Aguirre-Ghiso J . The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer. 2021; 1(7):672-680. PMC: 7929485. DOI: 10.1038/s43018-020-0088-5. View

Ghayad S, Vendrell J, Ben Larbi S, Dumontet C, Bieche I, Cohen P . Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2009; 126(2):545-62. DOI: 10.1002/ijc.24750. View

Watson G, Ronai Z, Lau E . ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease. Pharmacol Res. 2017; 119:347-357. PMC: 5457671. DOI: 10.1016/j.phrs.2017.02.004. View

Yu Q, Verheyen E, Arial Zeng Y . Mammary Development and Breast Cancer: A Wnt Perspective. Cancers (Basel). 2016; 8(7). PMC: 4963807. DOI: 10.3390/cancers8070065. View

Brooks M, Burness M, Wicha M . Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell. 2015; 17(3):260-71. PMC: 4560840. DOI: 10.1016/j.stem.2015.08.014. View

Gomez B, Riggins R, Shajahan A, Klimach U, Wang A, Crawford A . Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J. 2007; 21(14):4013-27. DOI: 10.1096/fj.06-7990com. View

10.

Arrowsmith C, Bountra C, Fish P, Lee K, Schapira M . Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012; 11(5):384-400. DOI: 10.1038/nrd3674. View

11.

Hengel S, Murray E, Langdon S, Hayward L, ODonoghue J, Panchaud A . Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance. J Proteome Res. 2011; 10(10):4567-78. PMC: 3242698. DOI: 10.1021/pr2004117. View

12.

Novak D, Huser L, Elton J, Umansky V, Altevogt P, Utikal J . SOX2 in development and cancer biology. Semin Cancer Biol. 2019; 67(Pt 1):74-82. DOI: 10.1016/j.semcancer.2019.08.007. View

13.

Fu X, Jeselsohn R, Pereira R, Hollingsworth E, Creighton C, Li F . FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016; 113(43):E6600-E6609. PMC: 5087040. DOI: 10.1073/pnas.1612835113. View

14.

Guan J, Zhou W, Hafner M, Blake R, Chalouni C, Chen I . Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. Cell. 2019; 178(4):949-963.e18. DOI: 10.1016/j.cell.2019.06.026. View

15.

Huebner K, Prochazka J, Monteiro A, Mahadevan V, Schneider-Stock R . The activating transcription factor 2: an influencer of cancer progression. Mutagenesis. 2019; 34(5-6):375-389. PMC: 6923166. DOI: 10.1093/mutage/gez041. View

16.

Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L, Coombes R . Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Res. 2014; 16(3):R62. PMC: 4095694. DOI: 10.1186/bcr3675. View

17.

Dittmer A, Dittmer J . Long-term exposure to carcinoma-associated fibroblasts makes breast cancer cells addictive to integrin β1. Oncotarget. 2018; 9(31):22079-22094. PMC: 5955132. DOI: 10.18632/oncotarget.25183. View

18.

Stone A, Zotenko E, Locke W, Korbie D, Millar E, Pidsley R . DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. Nat Commun. 2015; 6:7758. PMC: 4510968. DOI: 10.1038/ncomms8758. View

19.

Li Z, Zhu Q, Chen H, Hu L, Negi H, Zheng Y . Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer. Cancer Lett. 2016; 377(1):32-43. DOI: 10.1016/j.canlet.2016.04.003. View

20.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View